Onconetix (ONCO) Preferred Stock Liabilities (2023 - 2026)
Onconetix (ONCO) posted quarterly Preferred Stock Liabilities of $1724.0 for Q1 2026, down 99.67% year-over-year from $520000.0 in Q1 2025, and up 1.41% quarter-over-quarter from $1700.0 in Q4 2025.
Onconetix (ONCO) Preferred Stock Liabilities (2023 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Preferred Stock Liabilities for 4 consecutive years, with $1724.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Preferred Stock Liabilities fell 99.67% year-over-year to $1724.0; the TTM figure through Mar 2026 stood at $1724.0 (down 99.67% YoY), while the FY2025 annual figure was $1700.0, down 99.84% from the prior year.
- Preferred Stock Liabilities grew to $1724.0 in Q1 2026 per ONCO's latest filing, from $1700.0 in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $64.2 million in Q4 2023 and bottomed at $1700.0 in Q4 2025.
- Historically, Preferred Stock Liabilities has averaged $21.8 million across 4 years, with a median of $1.1 million in 2024.
- Annual changes were most pronounced in 2024 — Preferred Stock Liabilities plunged 98.34% — and 2025, when it sank 99.84%.
- Onconetix's Preferred Stock Liabilities stood at $64.2 million in 2023, then slumped by 98.34% to $1.1 million in 2024, then tumbled by 99.84% to $1700.0 in 2025, then climbed by 1.41% to $1724.0 in 2026.
- Business Quant data shows ONCO's Preferred Stock Liabilities at $1724.0 in Q1 2026, $1700.0 in Q4 2025, and $1.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 | 1.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.70 Mn |
| Mar 31, 2026 | 1,724.00 |
| Dec 31, 2025 | 1,700.00 |
| Sep 30, 2025 | 1.70 Mn |
| Jun 30, 2025 | 443,443.00 |
| Mar 31, 2025 | 520,000.00 |
| Dec 31, 2024 | 1.07 Mn |
| Jun 30, 2024 | 64.24 Mn |
| Mar 31, 2024 | 64.24 Mn |
| Dec 31, 2023 | 64.24 Mn |